Abstract: The object of the present invention is to provide novel compounds corresponding to the A ring part of vitamin D derivatives having a substituent at the 2-position. According to the present invention, there are provided compounds of the general formula (1): (wherein R1, R2 and R3, which may be the same or different, represent a hydrogen atom or a protecting group and R4 represents a lower alkyl group), intermediates for synthesizing them and a process for preparing them.

Abstract: A cis-olefin of the formula: R1—CH═CH—R2 is prepared by reducing an alkyne of the formula: R1—C≡C—R2 with formic acid in the presence of a palladium catalyst. R1 and R2 are independently selected from the group consisting of a hydrogen atom, ester group, substituted silyl group, carboxyl group, cyano group, aliphatic C1-C20 hydrocarbon group, and phenyl group. The cis-olefin which is a useful intermediate for the synthesis of fine chemicals is selectively produced in high yields.

Abstract: This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists.

Abstract: Novel amidinium derivatives of formula (I), wherein R1 is a cholesterol derivative or an alkylamino-NR′R″ grouping, and each of R2 and R3 is independently a hydrogen atom or a grouping of formula (II), wherein each of R4 and R5 is independently a hydrogen atom or a grouping of formula (III), are disclosed. The corresponding pharmaceutical compositions, which are particularly useful in gene therapy for transferring therapeutic genes into cells, are also disclosed.

Abstract: A cationic dyeability modifier for incorporation into polyesters and polyamides to increase their affinity for basic dyes, said cationic dyeability modifier having the following formula: R1OOC—(CH2)n—CH(CH2CH2SO3X)—(CH2)m—COOR2 where n is an integer from 1 to 10, m is an integer from 1 to 10, X is an alkali metal selected from the group consisting of lithium, sodium and potassium, and R1 and R2 are independently selected from hydrogen and alkyl groups having one to four carbon atoms is disclosed. Basic dyeable copolyesters and copolyamides containing the cationic dyeability modifier incorporated into the polymer chain of the copolymer are also disclosed. A process for preparing a basic dyeable copolyester by combining poly(alkylene terephthalate)-forming monomers or polyoxyalkylene glycol oligomers with the cationic dyeability modifier, and mixing and heating at a temperature sufficient to cause copolymerization to form a copolyester is also disclosed.

Abstract: The present invention relates to a method of catalyzing etherification, esterification, hydration, ether cleavage, isomerization alkylation, or other reactions which are catalyzable with an acid or molecular sieve catalyst. Said reactions are conducted using a novel, dual functional catalyst prepared with active components and a small amount of binder, wherein said dual functional catalyst comprises cylindrical pellets which are molded such that a cross-section or each pellet has a window lattice shape with external teeth, or a star shape with inner spokes.

Abstract: A process is disclosed for the esterification of an amino acid or peptide in which the amino acid or peptide is converted into the corresponding ester in the presence of a hydrosulphate have the general formula ROSO3H, where R represents an alkyl group, with the hydrosulphate being prepared, in the presence of the amino acid or peptide, from chlorosulphonic acid and an alcohol having the general formula ROH, where R has the same meaning as above. The chlorosulphonic acid to amino acid or peptide molar ratio preferably is between 0.8 and 2.0, in particular between 1.0 and 1.3. A primary alcohol, in particular methanol, is preferably used as alcohol. The amino acid used may be for example an &agr;-amino acid chosen from the group comprising p-hydroxyphenylglycine, phenylglycine, phenylalanine, tyrosine, proline and valine; L-alanyl-L-proline or an ester of L-aspartyl-L-phenylalanine, for example, may be used as peptide.

Abstract: The invention relates to precursors of the A-ring of vitamin D, of the formula (I): in which A, R, R1 and R2 are as defined in the specification. The invention also relates to a method of preparing compounds (I) comprising the enzymatic asymmetrization of 3,5-dihydroxybenzoic acid derivatives, as well as intermediates of preparation of said compounds.

Abstract: The use of 2-methyl-3-cyclohexylpropanol, esters thereof or mixtures thereof as fragrance materials is disclosed. The subject materials possess unique fragrance notes and are cost-effective materials. The esters are novel compounds.

Abstract: A peptide-amphiphile complex having a lipophilic portion and a peptide portion, wherein the peptide portion has a secondary structure.

Abstract: The present invention provides a chemically modified form of hemoglobin that is stabilized and can efficiently bind and release oxygen. In addition the chemically modified hemoglobin may be polymerized to increase its molecular weight and increase its stability so that it will have a longer half life in the circulatory system and may be used as a stable oxygen transport mediator which is useful as the basis of a blood substitute.

Abstract: Methyl 2-(chloro- or bromomethyl)phenylacetate is prepared by treating 3-isochromanone with thionyl chloride or thionyl bromide in the presence of methanol.

Abstract: Dibenzodihydropyridinecarboxylic esters are provided which comply with formula (1) or (2), wherein: R.sub.1 is substituted alkyl or cyano; R.sub.2 and R.sub.3 are independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; R.sub.4 is hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; R.sub.5 and R.sub.6 are independently alkyl, alkoxy or another substituent which is relatively resistant to oxidation; m and n are integers from 0 to 4; wherein, if m or n is at least 2, two groups R.sub.5 or R.sub.6 may be linked together; and Z is oxygen or sulphur. The new compounds are used in a method as chemiluminogenic reagents for detecting the presence of peroxidase activity at extremely low levels (10.sub.-20 moles). A kit containing the dibenzodihydropyridine-carboxylic esters for use in assaying peroxidase activity has also been described.

Abstract: The invention relates to a chiral solid catalyst containing a BEA topology zeolite and a metal-binap complex and to a process for the production of substantially enantiomerically pure products from prochiral starting material with the catalyst. The BEA topology zeolite may be a BETA zeolite, an acid BEA topology zeolite, an acid NU-2 zeolite, or an ammonium BEA topology zeolite. The metal in the metal-binap complex is ruthenium, iridium, nickel, or rhodium. The zeolite is normally impregnated with a solution of the metal-binap complex. The method is applicable to asymmetric hydrogenation of beta functionalized ketones, betaketoesters, functionalized olefins, and .alpha., .beta.-unsaturated functionalized olefins.

Abstract: A process for preparing 1,6-hexanediol comprising hydrogenating a starting material containing at least one compound selected from the group consisting of adipic acid, .epsilon.-hydroxycaproic acid, .epsilon.-caprolactone and oligomers of .epsilon.-caprolactone, preferably a substance recovered from a reaction mixture resulting from liquid phase oxidization of cyclohexane for the production of cyclohexanol and cyclohexanone, in a liquid phase in the presence of a solid catalyst containing ruthenium and tin.

Abstract: The present invention provides a chemically modified form of hemoglobin that is stabilized and can efficiently bind and release oxygen. In addition the chemically modified hemoglobin may be polymerized to increase its molecular weight and increase its stability so that it will have a longer half life in the circulatory system and may be used as a stable oxygen transport mediator which is useful as the basis of a blood substitute.

Abstract: The invention relates to a process for the preparation of highly concentrated free-flowing and pumpable aqueous solutions of betaines by quaternization of a compound which contains tertiary amine nitrogen with a .omega.-halo carboxylic acid characterized in that 0.5-5% by weight of the final product, of a viscosity-reducing compound such as an alkali or alkaline earth metal citric acid salt is added to the reaction mixture before or during the quaternization reaction.

Abstract: The present invention is concerned with photo cross-linkable liquid crystalline compounds of the general formula ##STR1## wherein A.sup.1 and A.sup.2 each represent a cross-linkable, mesogenic residue,liquid crystalline mixtures which contain such compounds and their use in the cross-linked state as optical components.

Abstract: The present invention relates to a process for recovering polyhydroxyalkanoate from a biological source material comprising the polyhydroxyalkanoate, the process comprising: a) comminuting the biological source material; b) air classifying the biological source material such that the polyhydroxyalkanoate particles are separated from other components of the biological source material; and c) recovering the polyhydroxyalkanoate.

Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.

Abstract: Enzymatically cleavable chemiluminescent 1,2-dioxetane compounds capable of producing light energy when decomposed, substantially stable at room temperature before a bond by which an enzymatically cleavable labile substituent thereof is intentionally cleaved, are disclosed. These compounds can be represented by the formula: ##STR1## wherein: X and X.sup.1 each represent, individually, hydrogen, a hydroxyl group, a halo substituent, an unsubstituted lower alkyl group, a hydroxy (lower) alkyl group, a halo (lower) alkyl group, a phenyl group, a halophenyl group, an alkoxyphenyl group, a hydroxyalkoxy group, a cyano group or an amide group, with at least one of X and X.sup.1 being other than hydrogen; andR.sub.1 and R.sub.2, individually or together, represent an organic substituent that does not interfere with the production of light when the dioxetane compound is enzymatically cleaved and that satisfies the valence of the dioxetane compound's 4-carbon atom, with the provisos that if R.sup.1 and R.sub.

Abstract: A method of using vitamin D derivatives of the formula ##STR1## wherein X is .dbd.CH.sub.2 or H,H;Y is a moiety--CH(CH.sub.3)--(A).sub.n --C(O)--OR.sup.1 (a)--CH(CH.sub.3)--CH.sub.2 --O--C(O)--R.sup.2 (b)or--C(O)--OR.sup.1 (c);A is --CH.dbd.CH-- or CH.sub.2 --CH.sub.2 --R.sup.1 is lower alkyl, cycloalkyl, cycloalkylmethyl, --CH.sub.2 R.sup.3 or --CH.sub.2 --CH.sub.2 R.sup.3 ;R.sup.2 is lower alkyl, cycloalkyl or R.sup.3 ;R.sup.3 is hydroxy-lower alkyl, hydroxy-cycloalkyl or trifluoromethyl-hydroxy-lower-alkyl;n is 0 or 1;and the dotted bond in the five membered ring is optional;in the treatment of dermatological conditions, in particular keratinization disorders such as psoriasis, as well as acne and photodamaged skin, is described.Vitamin D derivatives of the formula I above, wherein X, Y, A, R.sup.1, R.sup.2, R.sup.3 and n are as set forth above; with the proviso that X is H,H when Y is --CH(CH.sub.3)--CH.sub.2 --OC(O)--C(OH)(CH.sub.3).sub.

Abstract: Known (R)-1-aryl-alkylamines of the formula ##STR1## in whichR.sup.1 and Ar have the meanings indicated in the description, are prepared by a new process, which comprisesa) reacting a racemate of an ethyl or methyl 2-aryl-alkanoate of the formula ##STR2## with ammonia in the presence of a lipase which is suitable for the cleavage of esters, in the presence of a diluent,b) separating off from the reaction mixture the resulting (R)-2-aryl-alkanamide of the formula ##STR3## and then reacting it with sodium hypochlorite or sodium hypobromite in the presence of water.

Abstract: The present invention provides a process for preparation of an ester comprising reacting a carboxylic acid and an alcohol in the presence of an esterific catalyst comprising at least one compound selected from the group consisting of halides, nitrates, carboxylates, alcoholates and acetylacetone complexes of metals of the titanium group. According to the present process, substantially equal equivalent of the alcohol and the acid can be reacted completely. In addition, the present invention further provides a purification process to eliminate the catalyst from homogeneous reaction system completely.

Abstract: The invention relates to a water-soluble, haemolytically inactive dextran fatty carboxylate with amphiphilic properties made from a dextran with an average molecular weight of 5,000 to 100,000 and a C.sub.10 to C.sub.14 fatty acid, preferably a C.sub.12 fatty acid, wherein the average degree of substitution is between 0.005 and 0.15 and is adjusted, depending on the average molecular weight of the dextran fatty carboxylate and the chain-length of the fatty acid used, in such a way that the dextran fatty carboxylate is soluble in water at room temperature, a process for its preparation and pharmaceutical or cosmetic preparations which contain it as solubilizer.

Abstract: Dienes of the formula I ##STR1## in which n is 0, 1, 2, 3, 4 or 5,r is 1, 2 or 3,s is 1 or 2, ##STR2## is trans-1,4-cyclohexylene or trans-1,3-dioxane-2,5-diyl, ##STR3## is trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, unfluorinated or mono- or polyfluorinated 1,4-phenylene, in which one or two CH groups may also be replaced by N, or the central part ##STR4## Z is a single bond, a bridging member selected from the group consisting of --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CO--O--, --CH.sub.2 O--, --OCH.sub.2 -- and --O--CO--, or any desired combination of two such bridging members, where two O atoms are not linked directly to one another, andR is --CN, --NCS, halogen or an alkyl, alkenyl, alkoxy or alkenyloxy group, in each case having up to 12 carbon atoms and in each case unsubstituted or monosubstituted or polysubstituted by fluorine and/or chlorine.

Abstract: The invention concerns perfumes containing as fragrance materials 1,4-dimethyl-cyclohexane-1-carboxylic acid esters of general formula wherein R is an alk(en)yl group having 1-4 carbon atoms, preferably R$(1,3)methyl. The fragrance materials have very agreable fresh herbal ordours with green and floral notes.

Abstract: Disclosed is an apparatus and process for producing a tripropylene glycol in which alkylene oxide, water, an acid catalyst and a dipropylene glycol are contacted together under conditions suitable to form the tripropylene glycol. Water is present in the reaction mixture in the range of about 1 to about 50 weight percent of the reaction mixture. The ratio of water to alkylene oxide is less than about 9. The tripropylene glycol thus produced exhibits a higher primary hydroxyl group content generally exceeding 36 percent. Such tripropylene glycols find utility in the production of acrylics. Also disclosed is a process for making esters from such glycols.

Abstract: Nitrogen-free anionic conditioning formulations containing sulfated polyol fatty acid esters corresponding to formula (I): ##STR1## in which R.sup.1 CO is a linear or branched, saturated or unsaturated acyl radical containing 6 to 22 carbon atoms, R.sup.2 represents hydrogen, an OCR.sup.1 group or an SO.sub.3 X group, R.sup.3 is hydrogen or an (OCH.sub.2 CH.sub.2).sub.m OR.sup.2 group, n is 0 or a number of 1 to 5, m is 0 or a number of 1 to 10, and X is an alkali metal, alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium ion.

Abstract: The compounds of formula ##STR1## wherein the Z group can be located in positions ortho-, meta- or para-relative to the carboxylic group, symbol R.sup.1 stands for a saturated or unsaturated, linear or branched C.sub.1 to C.sub.4 alkyl radical anda. the dotted lines represent a cyclohexanic moiety and Z represents a ##STR2## group, R.sup.2 being a saturated or unsaturated, linear or branched C.sub.1 to C.sub.4 alkyl radical; orb. the dotted lines represent a cyclohexanic or benzenic moiety and Z represents a group of formula ##STR3## in which R.sup.2 is a saturated or unsaturated, linear or branched C.sub.1 to C.sub.4 alkyl radical, are useful as perfuming ingredients for the preparation of perfuming compositions and a variety of perfumed consumer articles. They impart to the latter odor notes of the fruity and floral type.

Abstract: This invention features permeability enhancer molecules, and methods, to increase membrane permeability of negatively charged polymers thereby facilitating cellular uptake of such polymers.

Abstract: p-Hydroxyaniline derivatives of the formula I ##STR1## where the substituents have the following meanings: R.sup.1 is hydrogen, or unsubstituted or substituted alkyl;R.sup.2 and R.sup.3 independently of one another are halogen, alkyl, haloalkyl, alkoxy or haloalkoxy;R.sup.4 is unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl,OR.sup.5 or NR.sup.6 R.sup.7, whereR.sup.5, R.sup.6 are unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl, andR.sup.7 is hydrogen or alkyl,and their salts, processes for their preparation, compositions containing them and their use for controlling harmful fungi or pests, and also compounds of the formula VI ##STR2## and their salts, processes for their preparation, compositions containing them and their use as intermediates and for controlling pests are described.

Abstract: Novel compounds of Formula 1 ##STR1## or a pharmaceutically acceptable salt or solvate thereof are disclosed. Also disclosed are pharmaceutical compositions containing compounds of Formula 1. Methods of treating allergy, inflammation and hyperproliferative skin diseases with compounds of Formula 1 are also disclosed.

Abstract: A test device for determining the presence of leukocyte cells, esterase or protease in a test sample is disclosed. The test device comprises a carrier matrix having a reagent composition incorporated therein, wherein the reagent composition comprises a lactate ester having the structure ##STR1## wherein A is an alcohol blocking group, and wherein B--O-- is a residue of compound B--OH and provides a detectable response when the lactate ester is hydrolyzed; and a buffer. In a preferred embodiment, the lactate ester has the structure ##STR2## wherein X is O, S or NR.sup.2, R is aryl or lower alkyl, R.sup.1 is hydrogen or lower alkyl, and R.sup.2 is hydrogen, lower alkyl or aryl.

Abstract: This invention relates to a block copolymer comprising: a) at least one first block of polymerized units of at least one first ethylenically unsaturated monomer and at least one latent thiol mercaptan chain transfer agent wherein the latent thiol mercaptan chain transfer agent has the general formula; ##STR1## wherein A is a polyvalent organic radical; x and y are positive integers such that x+y equals the valence of A; B is an organic acyl radical; and n and m are integers from 1 to 6; and b) at least one second block of polymerized units of at least one second ethylenically unsaturated monomer, wherein said at least one second block is attached to said at least one first block by reacting with terminal thiol functional groups contained on said at least one first block. In addition, this invention relates to the method of making this block copolymer.

Abstract: This invention relates to a polymer composition of a block copolymer dispersed in water wherein the block copolymer is composed of: a) at least one first block of polymerized units of at least one first ethylenically unsaturated monomer and at least one latent thiol mercaptan chain transfer agent wherein the latent thiol mercaptan chain transfer agent has the general formula; ##STR1## wherein A is a polyvalent organic radical; x and y are positive integers such that x+y equals the valence of A; B is an organic acyl radical; and n and m are integers from 1 to 6; and b) at least one second block of polymerized units of at feast one second ethylenically unsaturated monomer, wherein said at least one second block is attached to said at least one first block by reacting with terminal thiol functional groups contained on said at least one first block.

Abstract: Allylaminoesters of the formula (I): ##STR1## in which: R.sub.1 is H or low-molecular-weight alkyl,R.sub.2 is low-molecular-weight alkyl, cycloalkyl, or low-molecular-weight phenylcycloalkyl, pyridyl or phenyl, low-molecular-weight phenylalkyl, low-molecular-weight diphenylalkyl, low-molecular-weight phenylalkenyl, in which the phenyl cycle may be mono-, di- or trisubstituted by chlorine atoms, low-molecular-weight alkyl radicals, low-molecular-weight alkoxy, or trifluoromethyl, acetamide or acetyloxy radicals, their racemic forms, their (S) enantiomers and their addition salts. Also, antiallergic drugs containing the same.

Abstract: A composition and method for determining the presence of leukocyte cells, esterase or protease in a test sample are disclosed. The composition contains a lactate ester having the structure ##STR1## wherein A is an alcohol blocking group, and wherein B-O- is a residue of compound B-OH and provides a detectable response when the lactate ester is hydrolyzed; and a buffer. One class of lactate ester has the structure ##STR2## wherein X is O, S or NR.sup.2, R is aryl or lower alkyl, R.sup.1 is hydrogen or lower alkyl, and R.sup.2 is hydrogen, lower alkyl or aryl.

Abstract: There are disclosed hydrazone derivatives of the general formula [I]: ##STR1## wherein R.sup.1 is halogen, etc.; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl, etc.; R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl, etc.; R.sup.4 is hydrogen or C.sub.1 -C.sub.6 alkyl, etc.; R.sup.5 is C.sub.1 -C.sub.6 alkyl, etc.; R.sup.6 is hydrogen or C.sub.1 -C.sub.6 alkyl, etc.; A is (CH.sub.2).sub.t, O, S(O).sub.n, etc.; a is an integer of 1 to 4; n is an integer of 0 to 2; and t is an integer of 1 to 3; as well as production processes therefor, insecticides and/or acaricides containing the same as an active ingredient and intermediate compounds thereof.

Abstract: The present invention relates to a homogeneous, ruthenium catalyzed liquid phase process for vinyl ester synthesis. It has been found that by adding at least one selectivity enhancer to the reaction system, selectivity to the addition reaction is improved while byproduct formation is inhibited. Useful selectivity enhancers include non-reacting heteroatom containing molecules that are believed to act by weakly coordinating to the ruthenium/phosphine ligand complex.

Abstract: A process for preparing monocarboxylic esters of the general formula I ##STR1## where R.sup.1 and R.sup.2 are each hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cyclo-alkyl acyl, aryl or C.sub.7 -C.sub.20 -aralkyl or together --(CH.sub.2).sub.n --X--(CH.sub.2).sub.m --,X is methylene, oxygen, sulfur, NH or NR.sup.3,R.sup.3 is C.sub.1 -C.sub.12 -alkyl, andn and m are each from 0 to 8, comprises reacting geminal dicarboxylic esters of the general formula II ##STR2## where R.sup.1 to R.sup.3 are each as defined above, at from 150.degree. to 400.degree. C. in the presence of catalysts.

Abstract: This invention relates to latent thiol mercaptan chain transfer agents and their use in the synthesis of polymers. In addition, this invention relates to novel polymers and block copolymers formed using these latent thiol mercaptan chain transfer agents.

Abstract: This invention relates to latent thiol mercaptan chain transfer agents and their use in the synthesis of polymers. In addition, this invention relates to novel polymers and block copolymers formed using these latent thiol mercaptan chain transfer agents.

Abstract: Ethyl (1R,6S)-2,2,6-trimethylcyclohexanecarboxylate represented by formula (1) ##STR1## is disclosed. Also, an aroma chemical composition containing the same and a process of the production of the same are disclosed.

Abstract: Antihypercholesterolemic activity is exhibited by compounds of the formula ##STR1## wherein: X is hydrogen, alkali metal or ammonium;Y is hydrogen, alkyl, cycloalkyl, aryl, or aralkyl; ##STR2## R is hydrogen, alkyl, ammonium, alkylammonium, or alkali metal (such as Na, Li, or K); andn is 1 or 2.

Abstract: A phenylbicyclohexanol ester derivative which is a nematic liquid crystal compound having a weakly positive dielectric anisotropy is disclosed. This compound has a high N-I point and yet a low .DELTA.n value. When mixed with other nematic liquid crystal compound(s), it can give a liquid crystal display cell material having excellent visual properties and high-temperature driving properties.

Abstract: A process is disclosed for the enantioselective hydrogenation of olefins of the formula: ##STR1## where R is hydrogen or C.sub.1 to C.sub.6 linear or branched alkyl, Z is ##STR2## where R' is hydrogen or C.sub.1 to C.sub.6 linear or branched alkyl, --CN, C(NH)OR" where R" is C.sub.1 to C.sub.6 linear or branched alkyl, or --C(O)NH.sub.2 ; and Ar is phenyl or naphthyl unsubstituted or substituted with benzoyl or substituted benzoyl, C.sub.1 to C.sub.6 linear or branched alkyl, C.sub.1 to C.sub.6 linear or branched alkoxy, halo, or carboxylic acid or C.sub.1 to C.sub.6 linear or branched alkyl ester thereof, which comprises contacting said aromatic-substituted olefin with a catalytically effective amount of a ruthenium phosphite complex.

Abstract: Compounds of the formula ##STR1## wherein n stands for the number 0 or 1; the rings A.sup.1, A.sup.2 and A.sup.3 represent 1,4-phenylene, 2-fluoro-1,4-phenylene or trans-1,4-cyclohexylene or one of these rings also represents a 2,5-disubstituted pyrimidine ring or a trans-2,5-disubstituted m-dioxane ring; X.sup.1 represents a single covalent bond, --COO--, --OOC--, --CH.sub.2 CH.sub.2 --, p--C.sub.6 H.sub.4 --, --CH.sub.2 CH.sub.2 --p-- C.sub.6 H.sub.4 --, --CH.sub.2 CH.sub.2 --p--C.sub.6 H.sub.4 --CH.sub.2 CH.sub.2 -- or, insofar as the rings A.sup.1 and A.sup.2 represent 1,4-phenylene, also --NON--; R.sup.2 represents 1E-alkenyl, 2Z-alkenyl, 3E-alkenyl, 4-alkenyl or alkenyloxy, with the proviso that the oxygen atom in alkenyloxy is linked with a saturated carbon atom; and R.sup.1 signifies 1E-alkenyl, 2Z-alkenyl, 3E-alkenyl, 4-alkenyl or, insofar as R.sup.2 represents alkenyloxy, also alkyl, their manufacture, as well as liquid crystalline mixtures and the use for electro-optical purposes.

Abstract: Novel sulfonium salts useful as photoinitiators for cationic polymerization and for producing relief patterns and relief images have the general formula (I) ##STR1## where A.sup..crclbar. is a non-nucleophilic counterion,x is 1, 2 or 3,R is a hydrocarbon radicalR' is arylene or substituted arylene, andR" is ##STR2## where R.sup.1, R.sup.2 and R.sup.3 are each alkyl or monohalogenated or polyhalogenated alkyl orR.sup.1 and R.sup.2 are each hydrogen or alkyl, and R.sup.3 is phenyl, alkenyl or cycloalkenyl, orR.sup.1 is hydrogen, and R.sup.2 and R.sup.3 form ethylenically unsaturated ring, orR.sup.1 and R.sup.2 are each hydrogen, alkyl, cycloalkyl or aryl, and R.sup.3 is alkoxy orR.sup.1 is hydrogen or alkyl and R.sup.2 and R.sup.3 are each alkoxy, aryloxy or substituted aryloxy.

Abstract: A 1,3,2-dioxathiolane oxide derivative is represented by the following formula: ##STR1## wherein X represents --S(O)-- or --S(O).sub.2 --;R.sup.1 represents a hydrogen atom, an alkali metal atom, a benzyl group, or a lower alkyl group;R.sup.2 represents a lower alkyl group which may be substituted with a methylthio group, or a benzyl group, andR.sup.3 and R.sup.4 may be the same or different and independently represent a hydrogen atom, an alkyl group having one to ten carbon atoms, a lower alkyl group substituted with a guanidyl group, a cycloalkyl group having 3 to 6 carbon atoms, a phenyl group, a benzyl group, or a phenethyl group, or together form an alkylene group.